Sun Pharma gains on U.S. nod for cancer drug
Reuters Market Eye - Shares in Sun Pharmaceutical Industries Ltd (SUN.NS) rose as much as 4.5 percent after the U.S. Food and Drug Administration approved its generic version of ovarian cancer drug Doxil made by Johnson & Johnson (JNJ.N) in the U.S. market.
"Doxil generic approval came in as a positive surprise. This would add US$70-$100m in high margin sales for FY14 until further generic competition comes in," CLSA said in a note on Tuesday.
Shares in the drugmaker also gained after subsidiary Taro Pharmaceutical Industries Ltd (TARO.N) posted a 42 percent growth in October-December net profit.
Sun Pharma shares were up 3.5 percent as of 12:28 p.m.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
- Analysis - Amazon's far-reaching ambitions, lack of profits, unnerve investors
- U.S. diplomats' return to Libya could be more hazardous than exit
- Australia approves Adani's $16 bln Carmichael coal project
- Israel extends Gaza ceasefire for 24 hours, Hamas rejects terms
- U.S. gasoline prices tumble on back of refinery cuts- Lundberg survey
The Australian government on Monday approved Indian firm Adani Mining Pty Ltd's $15.5 billion Carmichael coal and rail project in Queensland, subject to strict conditions to protect groundwater. Full Article